ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

CTSO CytoSorbents Corporation

0.802
0.001 (0.12%)
After Hours
Last Updated: 16:30:00
Delayed by 15 minutes

Period:

Draw Mode:

Volume 46,299
Bid Price 0.7825
Ask Price 0.8499
News -
Day High 0.841

Low
0.782

52 Week Range

High
4.29

Day Low 0.79
Company Name Stock Ticker Symbol Market Type
CytoSorbents Corporation CTSO NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.001 0.12% 0.802 16:30:00
Open Price Low Price High Price Close Price Prev Close
0.81 0.79 0.841 0.802 0.801
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
380 46,299 $ 0.8012918 $ 37,099 - 0.782 - 4.29
Last Trade Time Type Quantity Stock Price Currency
16:13:35 1 $ 0.8133 USD

CytoSorbents Corporation Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
36.44M 44.44M - 36.35M -28.51M -0.64 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

CytoSorbents News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No CTSO Message Board. Create One! See More Posts on CTSO Message Board See More Message Board Posts

Historical CTSO Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.890.960.7820.822552785,683-0.088-9.89%
1 Month0.86011.020.7820.911957388,106-0.0581-6.76%
3 Months0.88321.060.7820.957231100,897-0.0812-9.19%
6 Months1.602.150.7821.14231,413-0.798-49.88%
1 Year3.094.290.7821.53150,079-2.29-74.05%
3 Years9.029.800.7823.79190,252-8.22-91.11%
5 Years7.2113.890.7826.05269,204-6.41-88.88%

CytoSorbents Description

CytoSorbents Corp is a critical care immunotherapy leader commercializing its European Union approved CytoSorb blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients in around 55 countries. The company is conducting its pivotal REFRESH 2 - AKI cardiac surgery trial, designed to support U.S. FDA approval. The company's product portfolio consists of CytoSorb, ContrastSorb, VetResQ, HemoDefend and others. The company has around 19 issued U.S. patents, multiple patents issued internationally, and a broad patent application portfolio pending. Geographically it derives substantial revenue from product sales in Germany.

Your Recent History

Delayed Upgrade Clock